Strongbrigde Biopharma 200 Prozent Potential?

Ausgehend vom aktuell Kurs zum KZ von 21USD

http://www.finanzen.net/analyse/...y-Stifel_Nicolaus__Co__Inc__558835

Pipeline

http://www.strongbridgebio.com/pipeline/  

https://www.analystratings.com/articles/...a-buy-from-h-c-wainwright/  

 

https://www.zacks.com/stock/news/608278/...=CS-ZC-FT-tale_of_the_tape|yseop_template_4-608278  

 

scheint nur eine Richtung zu kennen! Zumindest aktuell  

ich versuche das „aktuell“ auszublenden und mich auf „langfristig“ zu konzentrieren. Die Bewertung ist doch m.E. derzeit eher ein Witz. Vllt gelingt es mir ja, nicht ständig ins Depot zu schauen.  

Von Tief zu Tief....Finger weg! Meine Meinung.  

 

https://www.finanzen.net/nachricht/aktien/...nen-quartals-vor-8556399  

ohne News!  

https://seekingalpha.com/news/...eed_news_all&utm_medium=referral  

https://seekingalpha.com/news/...eed_news_all&utm_medium=referral  

 

 

https://www.analystratings.com/articles/...rongbridge-biopharma-sbbp/  

 

 

 

 

 

https://seekingalpha.com/article/...bing-the-strongbridge-acquisition

https://www.pharmatimes.com/news/...n_becomes_available_in_uk_1385622  

https://seekingalpha.com/news/...eed_news_all&utm_medium=referral


https://www.nasdaq.com/de/market-activity/stocks/xers/real-time  

Now what

Cushing's syndrome is rare, but patients display a variety of symptoms usually associated with more common diseases, including elevated blood pressure and blood sugar. As such, it's often misdiagnosed. The availability of a new tablet to treat the disorder could bring enough patients out of the woodwork to drive annual sales above $200 million in a few short years.

Recorlev wasn't the only rare disease drug Xeris acquired from Strongbridge. The company also picked up Keveyis. This is the first and only available treatment approved by the FDA to treat primary periodic paralysis.

During the first nine months of 2021, Keveyis sales rose 33% year over year to $30 million. With the addition of Recorlev to Xeris' product line, the company could feasibly begin generating annual sales above $100 million before the end of 2023.

At recent prices, Xeris Biopharma sports a very modest market cap of just $366 million. That seems extremely cheap for a company with several commercial-stage products. I wouldn't be surprised if this biotech stock shoots through the roof in the new year.

https://www.fool.com/investing/2021/12/31/...-stock-is-jumping-today/  

https://www.finanzen.net/nachricht/aktien/...hing-s-syndrome-10922686  

20 Prozent in einem Monat ist aktuell für einen Biotechtitel nicht schlecht, zumindest wenn es gen Norden geht! Aber nachhaltig sollten die 2,90 / 3 Dollar noch aus dem Weg geräumt werden...

https://www.nasdaq.com/de/market-activity/stocks/xers/real-time